Welcome to our dedicated page for Avalon Globocare news (Ticker: ALBT), a resource for investors and traders seeking the latest updates and insights on Avalon Globocare stock.
Avalon GloboCare Corp. (NASDAQ: ALBT) generates news across precision diagnostics, cellular therapy intellectual property, generative AI software, and commercial real estate. Company press releases describe Avalon as a commercial‑stage developer of precision diagnostic consumer products, with a flagship focus on the KetoAir™ handheld breathalyzer for ketogenic health management. News coverage frequently highlights deployments of KetoAir™ in wellness initiatives, first responder programs, and international online sales channels.
Investors following ALBT news will see updates on distribution agreements, affiliate marketing programs, and partnerships that incorporate KetoAir™ as a real‑time metabolic monitoring tool. Recent announcements include collaborations with Saga Health Corporation and SpecialtyHealth, Inc. for first responder wellness programs, as well as expansion of KetoAir™ availability into the United Kingdom through online sales. Avalon also reports on its co‑development agreement with Qi Diagnostics Limited to create a VOC nanosensor‑based cannabis breathalyzer aimed at supporting detection of potential cannabis‑impaired driving.
Beyond diagnostics, Avalon’s news flow includes developments in its cellular therapy intellectual property portfolio, such as the issuance of a Hong Kong patent for proprietary CAR‑T and CAR‑NK cell technology co‑developed with Arbele Limited. The company also issues updates on its acquisition of RPM Interactive, Inc. and the Catch‑Up generative AI SaaS platform, which is designed to automate short‑form video creation and support marketing for KetoAir™ and other consumer health products.
Regulatory and corporate actions also feature in ALBT news, including SEC filings, financing transactions, Nasdaq listing compliance updates, and progress on the proposed merger with YOOV Group Holding Limited. Readers can use this news stream to monitor how Avalon’s precision diagnostics, AI‑driven software, cellular therapy IP, and capital markets activities evolve over time.
Avalon GloboCare (NASDAQ: ALBT) closed a private placement priced at-the-market on Feb 27, 2026, selling 6,372,550 shares (or pre-funded warrants) with associated warrants at $0.51 per share, raising approximately $3.25 million of gross proceeds.
The financing includes Series A-1 and A-2 warrants to purchase up to 6,372,550 shares each, exercisable at $0.51 if and when stockholder approval is effective; A-1 expire five years and A-2 expire 18 months from stockholder approval. The company may receive up to ~$6.5 million more if warrants are fully exercised. Net proceeds are intended for debt repayment and working capital.
Avalon GloboCare (NASDAQ: ALBT) entered definitive agreements for a private placement to sell 6,372,550 shares (or pre-funded warrants) and associated Series A-1 and A-2 warrants at $0.51 per share.
The offering is expected to close on or about February 27, 2026, raising approximately $3.25 million in gross proceeds upfront and up to an additional $6.5 million if warrants are fully exercised. Net proceeds will be used to repay certain debt and for working capital.
Avalon GloboCare (NASDAQ: ALBT) was accepted into the AMD AI Developer Program on Feb. 26, 2026, giving its AI subsidiary AQAI access to AMD Developer Cloud credits, tools, training, and community resources.
Avalon plans to use AMD Instinct accelerators and EPYC processors to speed model training, inference, and scalability for automated evidence-constrained video generation, AI-assisted drafting, compliance tooling, and workflow automation.
Avalon GloboCare (NASDAQ: ALBT) subsidiary Avalon Quantum AI filed a U.S. provisional patent application (No. 63/961,892) on Feb 18, 2026 for an AI system that generates multiple audience-adaptive commentary video variants from a shared evidence framework while preserving factual integrity.
The platform is designed to tailor tone, pacing, and presentation by audience profile, collect performance data to refine strategies, and adapt outputs for short- and long-form formats, regional/regulatory requirements, and brand-safe distribution. Potential applications cited include personalized financial commentary, sports recaps, and marketing content.
Avalon GloboCare (NASDAQ: ALBT) announced conversion of the majority of its outstanding debentures from a June 2024 convertible note financing, strengthening its balance sheet and reducing overhang.
The financing had an aggregate principal of $2.8 million; $288,000 was repaid in cash and $2.6 million was converted into common stock, which the company believes has largely been sold. Avalon said the conversion improves financial transparency and supports its return to Nasdaq minimum stockholders' equity compliance while enabling progress on diagnostic and AI initiatives.
Avalon GloboCare (NASDAQ: ALBT) said subsidiary Avalon Quantum AI filed a U.S. provisional patent application (No. 63/961,889) on Jan 16, 2026 for “Systems and Methods for Evidence-Constrained, Audience-Adaptive Generation of Automated Commentary Videos.”
The filing describes an AI architecture that enforces evidence-linked generation, builds structured evidence graphs, detects source contradictions, applies uncertainty handling, and embeds traceability and audit metadata into video outputs to support editorial review, compliance validation, and accountability.
Avalon GloboCare (NASDAQ: ALBT) announced renewal of the U.S. FDA establishment registration for the KetoAir™ handheld breathalyzer (registration no. 3026284320). KetoAir measures breath acetone concentration (BrAce) using nanosensor technology to provide non-invasive metabolic and ketosis insights for users on ketogenic programs. Avalon plans a combined B2B and B2C launch for KetoAir via Catch-Up™, its generative AI short-form video SaaS, operated by Avalon Quantum AI, LLC. Marketing through Catch-Up™ is planned to begin in the second quarter of 2026 to support distribution, engagement, and adoption across enterprise and consumer channels.
Avalon GloboCare (NASDAQ: ALBT) announced it has regained compliance with the Nasdaq Capital Market's minimum stockholders' equity requirement under Rule 5550(b) and is now in compliance with all continued listing standards. The previously scheduled Nasdaq Hearings Panel session was cancelled and Avalon’s common stock will remain listed and traded on Nasdaq.
The company said restoring compliance supports its ability to pursue growth initiatives, including launching marketing for a generative AI video platform and expanding precision diagnostics and strategic assets.
Avalon GloboCare (NASDAQ: ALBT) announced the acquisition of RPM Interactive and highlighted RPM CEO and Avalon board member Michael Mathews discussing RPM’s Catch-Up generative AI video platform in a Dec. 30, 2025 interview.
Catch-Up is described as a SaaS platform that automatically generates recap-style videos using generative AI and large language models, planned for licensing to content creators, media companies and brands across news, sports, finance, entertainment and other categories. Avalon intends to use the platform to support marketing for KetoAir, its FDA-registered breathalyzer for metabolic wellness. The interview is available on ProactiveInvestors.com and on YouTube.
Avalon GloboCare (NASDAQ: ALBT) acquired RPM Interactive in an all-stock merger completed Dec. 12, 2025, effected by merging RPM into newly formed subsidiary Avalon Quantum AI, LLC.
Avalon issued 19,500 shares of Series E preferred (stated value $1,000/share; total purchase price $19.5 million) convertible at $1.50/share subject to a 4.99% ownership cap and conversion restrictions until May 12, 2026 and shareholder approval requirements. The company said this transaction brings stockholders’ equity above the $2.5 million Nasdaq minimum. RPM’s Catch-Up SaaS short-form generative AI video platform will support marketing for KetoAir™ and other consumer products.